MRIGlobal

DGAP-News: Sona Nanotech Engages MRIGlobal for COVID-19 Test Validation Studies

Retrieved on: 
Friday, May 22, 2020
Articles, Contents, Technology, Battelle Memorial Institute, Golden, Colorado, National Renewable Energy Laboratory, United States Department of Energy national laboratories, MRIGlobal, Emerging technologies, Sustainable energy, Nanotechnology, Nanoparticle, MRI Global, Sona Nanotech Inc.

Founded in 1944 as an independent, non-profit organization, we perform contract research for government, industry, and academia.

Key Points: 
  • Founded in 1944 as an independent, non-profit organization, we perform contract research for government, industry, and academia.
  • MRIGlobal is one of two partners in the Alliance for Sustainable Energy, LLC, which manages and operates the National Renewable Energy Laboratory (NREL) in Golden, Colorado, for the U.S. Department of Energy.
  • For more information, visit mriglobal.org
    Sona Nanotech Inc. is a nanotechnology life sciences firm that has developed multiple proprietary methods for the manufacture of various types of gold nanoparticles.
  • CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION: This press release includes certain "forward-looking statements" under applicable Canadian securities legislation.

MRIGlobal Continues Support Of Global Health, Launches New Line Of Custom Mobile Laboratories

Retrieved on: 
Monday, March 30, 2020
Safety, Surveillance, Institutes, Science, MRIGlobal, Knowledge, Biocontainment, Biosurveillance, Mobile laboratory, Laboratory

For nearly 20 years, MRIGlobal has been an industry leader in engineering, deploying, and staffing modular, portable laboratories for accurate infectious disease detection, surveillance, and response.

Key Points: 
  • For nearly 20 years, MRIGlobal has been an industry leader in engineering, deploying, and staffing modular, portable laboratories for accurate infectious disease detection, surveillance, and response.
  • Now, new versions of mobile laboratories are available to address a myriad of biological and chemical threats, with improved features.
  • MRIGlobal's mobile laboratory product line includes Athena, Mercury, and CBCS (Containerized BioContainment System).
  • Mercuryis a mobile molecular biosurveillance laboratory that can be transported and operated by one individual.

Coronavirus evacuees return safely to U.S. via innovative, MRIGlobal-designed biocontainment system

Retrieved on: 
Tuesday, February 18, 2020
Safety, Biological contamination, MRIGlobal, Biocontainment, Cargo, CBCS, D100, Institutes, Research, Organizations

The units are state-of-the-art, flight-ready containerized biocontainment systems (CBCS) that roll on and off planes.

Key Points: 
  • The units are state-of-the-art, flight-ready containerized biocontainment systems (CBCS) that roll on and off planes.
  • MRIGlobal designed the CBCS as a reusable bio-containment and medical treatment unit to operate on government/civilian cargo aircraft.
  • "It was developed to respond to critical global health situations like the coronavirus outbreak, and ultimately to save lives."
  • MRIGlobal's state-of-the-art, flight-ready Containerized Biocontainment System (CBCS) was awarded an R&D100 Award for Innovation by R&D Magazine in 2016.

Researchers Present Positive Interim Data on Appili Therapeutics’ ATI-1701 Biodefense Program at 2020 ASM Biothreats

Retrieved on: 
Tuesday, January 28, 2020
Infectious diseases, Biotechnology, Pharmaceutical, Health, Articles, Life sciences, Pharmacy, Health, American Society for Microbiology, Applied microbiology, MRIGlobal, Pharmaceutical industry, ASM, Biopharmaceutical

Appili Therapeutics Inc. (TSXV: APLI) (the Company or Appili), a biopharmaceutical company developing anti-infective drug candidates, today announced that Dr. Carl Gelhaus, Senior Program Manager of the Medical Countermeasures Division at MRIGlobal, will present positive interim data on Appilis ATI-1701 program at the 2020 ASM Biothreats conference .

Key Points: 
  • Appili Therapeutics Inc. (TSXV: APLI) (the Company or Appili), a biopharmaceutical company developing anti-infective drug candidates, today announced that Dr. Carl Gelhaus, Senior Program Manager of the Medical Countermeasures Division at MRIGlobal, will present positive interim data on Appilis ATI-1701 program at the 2020 ASM Biothreats conference .
  • We remain very encouraged by these results and look forward to sharing the 365-day challenge study data later this year.
  • Researchers will conduct an additional evaluation of vaccine efficacy up to 365 days in the same model in the first half of 2020.
  • Hosted by the American Society for Microbiology, ASM Biothreats offers a unique program that explores the latest developments and emerging technologies in the industry.

Researchers Present New Positive Interim Data on Appili Therapeutics’ ATI-1701 Biodefense Program at 2019 Chemical and Biological Defense Science & Technology Conference

Retrieved on: 
Monday, November 18, 2019
Biotechnology, Pharmaceutical, Health, Weapons of mass destruction, Defense Threat Reduction Agency, Nuclear proliferation, MRIGlobal, Institutes, Organizations, Research, ATI-1701, the Chemical and Biological Defense Science & Technology Conference (CBD S&T)

Appili Therapeutics Inc. (TSXV: APLI) (the Company or Appili), a biopharmaceutical company focused on anti-infective drug development, today announced that Dr. Carl Gelhaus, Senior Program Manager of the Medical Countermeasures Division at MRIGlobal, will present positive interim data on Appilis ATI-1701 program at the Chemical and Biological Defense Science & Technology Conference (CBD S&T).

Key Points: 
  • Appili Therapeutics Inc. (TSXV: APLI) (the Company or Appili), a biopharmaceutical company focused on anti-infective drug development, today announced that Dr. Carl Gelhaus, Senior Program Manager of the Medical Countermeasures Division at MRIGlobal, will present positive interim data on Appilis ATI-1701 program at the Chemical and Biological Defense Science & Technology Conference (CBD S&T).
  • Researchers will conduct an additional evaluation of vaccine efficacy up to 365 days in the same model in H1 2020.
  • The U.S. Defense Threat Reduction Agency (DTRA), an arm of the U.S. Department of Defense (DOD), is funding this trial.
  • Attendees will also network with DTRA science and technology managers as well as other members of DTRAs Chemical and Biological Defense team.

Ready For Action: Enhancements Completed On U.S. Army's State-Of-The-Art Chemical Defense Training Facility (CDTF) At Fort Leonard Wood

Retrieved on: 
Tuesday, April 9, 2019
CBRN defense, Emergency management, Radioactive contamination, Fort Leonard Wood, MRIGlobal, United States Army CBRN School, Institutes, U.S. Air Force Emergency Management

PULASKI, Mo., April 9, 2019 /PRNewswire/ -- Fort Leonard Wood Army Base --Dignitaries gathered to unveil the U.S. Army Chemical, Biological, Radiological, and Nuclear (CBRN) School, Chemical Defense Training Facility (CDTF) at Fort Leonard Wood, MO.

Key Points: 
  • PULASKI, Mo., April 9, 2019 /PRNewswire/ -- Fort Leonard Wood Army Base --Dignitaries gathered to unveil the U.S. Army Chemical, Biological, Radiological, and Nuclear (CBRN) School, Chemical Defense Training Facility (CDTF) at Fort Leonard Wood, MO.
  • Fully operational and the only facility of its kind within the U.S. Department of Defense, the CDTF will be the global venue of choice for live toxic CBRN defense training.
  • MRIGlobal designed and executed facility upgrades in concert with HHI Corporation fabrication and installation efforts.
  • Over the past year, Fort Leonard Wood has trained international partners from more than 63 nations.